MediWound Ltd. (NASDAQ:MDWD) Shares Bought by Silverberg Bernstein Capital Management LLC

Silverberg Bernstein Capital Management LLC boosted its stake in shares of MediWound Ltd. (NASDAQ:MDWD - Free Report) by 13.1% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 103,944 shares of the biopharmaceutical company's stock after buying an additional 12,060 shares during the period. MediWound accounts for about 1.5% of Silverberg Bernstein Capital Management LLC's investment portfolio, making the stock its 19th biggest holding. Silverberg Bernstein Capital Management LLC owned approximately 0.96% of MediWound worth $1,613,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently bought and sold shares of MDWD. GAMMA Investing LLC increased its position in shares of MediWound by 1,507.1% during the first quarter. GAMMA Investing LLC now owns 1,816 shares of the biopharmaceutical company's stock worth $28,000 after purchasing an additional 1,703 shares in the last quarter. R Squared Ltd acquired a new position in shares of MediWound during the fourth quarter worth $32,000. Russell Investments Group Ltd. increased its position in shares of MediWound by 154.1% during the fourth quarter. Russell Investments Group Ltd. now owns 1,916 shares of the biopharmaceutical company's stock worth $34,000 after purchasing an additional 1,162 shares in the last quarter. Bank of America Corp DE increased its position in shares of MediWound by 38.0% during the fourth quarter. Bank of America Corp DE now owns 7,915 shares of the biopharmaceutical company's stock worth $141,000 after purchasing an additional 2,178 shares in the last quarter. Finally, Rhumbline Advisers increased its position in shares of MediWound by 7.3% during the fourth quarter. Rhumbline Advisers now owns 10,835 shares of the biopharmaceutical company's stock worth $193,000 after purchasing an additional 739 shares in the last quarter. Hedge funds and other institutional investors own 46.83% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on MDWD shares. HC Wainwright set a $31.00 price target on MediWound and gave the stock a "buy" rating in a research report on Thursday, May 22nd. Craig Hallum started coverage on MediWound in a research report on Friday, February 28th. They issued a "buy" rating and a $39.00 target price on the stock. Alliance Global Partners started coverage on MediWound in a research report on Friday, May 2nd. They issued a "buy" rating and a $25.00 target price on the stock. Wall Street Zen raised MediWound to a "sell" rating in a research report on Friday, March 21st. Finally, Oppenheimer started coverage on MediWound in a research report on Monday. They issued an "outperform" rating and a $34.00 target price on the stock. One investment analyst has rated the stock with a sell rating and five have issued a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $31.80.

MediWound Stock Performance

Shares of NASDAQ MDWD traded down $0.07 during mid-day trading on Friday, hitting $21.60. The stock had a trading volume of 40,148 shares, compared to its average volume of 91,754. The company has a 50 day moving average of $18.33 and a two-hundred day moving average of $17.92. MediWound Ltd. has a twelve month low of $12.78 and a twelve month high of $24.00. The firm has a market cap of $233.45 million, a PE ratio of -7.45 and a beta of 0.38.

MediWound (NASDAQ:MDWD - Get Free Report) last announced its quarterly earnings results on Wednesday, May 21st. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.65) by $0.58. The company had revenue of $3.96 million for the quarter, compared to the consensus estimate of $5.20 million. MediWound had a negative return on equity of 82.17% and a negative net margin of 142.29%. During the same period last year, the firm earned ($1.05) EPS. Equities research analysts predict that MediWound Ltd. will post -2.66 EPS for the current fiscal year.

MediWound Company Profile

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.